StockpollyBeta
Get App
CRNX · NASDAQ · Biotechnology

Crinetics Pharmaceuticals (CRNX)

Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.

$84.95
0.00 (0.00%)
Delisted · Sep 2, 2026

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00100001061125
Cost of revenue046006267000000
Gross profit0−4610−62−6701061125
591774832628112130143140151157
Research & development44465358626776809085100100
151721252628365052545158
General & administrative15172125262836505254510
Other expenses0−4600−62−67000100
Operating income−59−63−74−83−88−95−111−129−143−134−140−132
23791114151312111312
Interest income37791114151313111312
Other non-operating income0−3−7−9−11−14−15−13−12−11−130
Income before tax−57−60−67−74−77−81−97−116−130−123−128−121
Income tax expense000000000000
Net income from continuing operations−57−60−67−74−77−81−97−116−130−123−128−121
Net income−57−60−67−74−77−81−97−116−130−123−128−121
EPS, basic−$1.01−$0.89−$0.93−$0.94−$0.96−$0.88−$1.04−$1.23−$1.38−$1.30−$1.23−$1.14
EPS, diluted−$1.01−$0.89−$0.93−$0.94−$0.96−$0.88−$1.04−$1.23−$1.38−$1.30−$1.23−$1.14
Weighted average shares, basic57677279809193949494104106
Weighted average shares, diluted57677279809193949494104106
EBITDA−59−60−66−73−76−80−96−115−129−122−127−131
Depreciation & amortization000111111111
EBIT−59−60−67−74−77−81−97−116−130−123−128−132